Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Anti-CD38-CAR IPS-Derived Cytotoxic T Lymphocytes Efficiently Eliminate Myeloma Cells Treated with Daratumumab and Isatuximab in Vitro and In Vivo

Yuji Hattori, Takanori Kubo, Seiji Nagano, Takahiko Miyama, Yoshitaka Taniguchi, Yoshitaka Iba, Nobuko Ohshima, Rie Kanehara, Takakazu Kawase, Masahide Takahashi, Hiroshi Kawamoto, Keichiro Mihara

Blood (2023) 142 (Supplement 1): 3312.

https://doi.org/10.1182/blood-2023-173356

Published: 2023

Journal Articles

T Cells Bearing Anti-CD19- and/or Anti-CD38-Chimeric Antigen Receptors Effectively Abrogate Primary Double-Hit Lymphoma Cells

Keichiro Mihara, MD PhD, Tetsumi Yoshida, MD, Yoshifumi Takei, MD PhD, Naomi Sasaki, MD PhD, Yoshihiro Takihara, MD PhD, Tatsuo Ichinohe, MD PhD

Blood (2016) 128 (22): 4182.

https://doi.org/10.1182/blood.V128.22.4182.4182

Published: 2016

Journal Articles

All-Trans Retinoic Acid and Interferon-Alpha Increase CD38 Expression on Adult T-Cell Leukemia Cells and Sensitize Them to T Cells Bearing Anti-CD38 Chimeric Antigen Receptors

Keichiro Mihara, MD PhD, Tetsumi Yoshida, MD, Seiko Ishida, MD PhD, Yoshifumi Takei, MD PhD, Akira Kitanaka, MD PhD, Kazuya Shimoda, MD PhD, Kazuhiro Morishita, MD PhD, Yoshihiro Takihara, MD PhD, Tatsuo Ichinohe, MD

Blood (2015) 126 (23): 591.

https://doi.org/10.1182/blood.V126.23.591.591

Published: 2015

Journal Articles

Adult T-Cell Leukemia/Lymphoma Cells Were Eliminated By T Cells With Anti-CD38 Chimeric Antigen Receptor Through CD38 Expression Induced By All-Trans Retinoic Acid

Tetsumi Yoshida, MD, Keichiro Mihara, MD, PhD, Akira Kitanaka, MD, PhD, Kazuya Shimoda, MD, PhD, Kazuhiro Morishita, MD, PhD, Yoshihiro Takihara, MD, PhD, Tatsuo Ichinohe, MD, PhD

Blood (2013) 122 (21): 1824.

https://doi.org/10.1182/blood.V122.21.1824.1824

Published: 2013

Journal Articles

All-Trans Retinoic Acid Enhances the Cytotoxic Effect of T Cells with Anti-CD38 Chimeric Receptor in Acute Myeloid Leukemia

Keichiro Mihara, MD, PhD, Joyeeta Bhattacharyya, MD, PhD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD

Blood (2012) 120 (21): 1901.

https://doi.org/10.1182/blood.V120.21.1901.1901

Published: 2012

Journal Articles

T-Cell Immunotherapy with a Chimeric Receptor Against CD38 Is Effective in Eliminating Myeloma Cells

Keichiro Mihara, MD, PhD, Joyeeta Bhattacharyya, MD, PhD, Akira Kitanaka, MD, PhD, Akihiro Ihara, MD, PhD, Akira Sakai, MD, PhD, Yoshiaki Kuroda, MD, PhD, Hideki Asaoku, MD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD

Blood (2011) 118 (21): 885.

https://doi.org/10.1182/blood.V118.21.885.885

Published: 2011

Journal Articles

B-Cell Lymphoma Cells Overexpressing BMI-1 Are Correlated with Drug Resistance through Enhanced Expression of Survivin and Are Effectively Eliminated by T Cells with Anti-CD38 Chimeric Receptor

Joyeeta Bhattacharyya, Keichiro Mihara, MD, PhD, Motoaki Ohtsubo, Shin'ichiro Yasunaga, MD, PhD, Yoshihiro Takihara, MD, PhD, Masaharu Hoshi, Akiro Kimura, MD, PhD

Blood (2010) 116 (21): 3613.

https://doi.org/10.1182/blood.V116.21.3613.3613

Published: 2010

Journal Articles

Synergistic and Persistent Effect of T-Cell Immunotherapy with Anti-CD19 or Anti-CD38 Chimeric Receptor on B-Cell Lymphoma in Conjunction with Rituximab

Keichiro Mihara, MD, PhD, Kazuyoshi Yanagihara, PhD, Misato Takigahira, PhD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD, PhD

Blood (2008) 112 (11): 2610.

https://doi.org/10.1182/blood.V112.11.2610.2610

Published: 2008

Journal Articles

Activated T Cell-Mediated Immunotherapy with a Chimeric Receptor Against CD38 in B-Cell Malignancies.

Keichiro Mihara, MD, PhD, Kazuyoshi Yanagihara, Ph.D, Misato Takigahira, Takahiro Ochiya, Ph.D, Chihaya Imai, M.D., Ph.D, Akira Kitanaka, M.D., Ph.D, Yoshihiro Takihara, M.D., Ph.D, Akiro Kimura, M.D., Ph.D

Blood (2007) 110 (11): 2356.

https://doi.org/10.1182/blood.V110.11.2356.2356

Published: 2007

Journal Articles

Interferon-γ Attenuates the Survival Activity of G-CSF through PI3K/Akt Signaling Pathway in Mouse Multipotent Progenitor Cells.

Hong Liu, MD, PhD, Keichiro Mihara, MD,Ph.D, Hideo Tanaka, MD,Ph.D, Akiro Kimura, MD,Ph.D

Blood (2006) 108 (11): 4163.

https://doi.org/10.1182/blood.V108.11.4163.4163

Published: 2006

Journal Articles

Mesenchymal Cells Determine the Response of Acute Lymphoblastic Leukemia Cells to L-Asparaginase.

Shotaro Iwamoto, MD, Keichiro Mihara, MD, PhD, James R. Downing, MD, Ching-Hon Pui, MD, Dario Campana, MD, PhD

Blood (2006) 108 (11): 833.

https://doi.org/10.1182/blood.V108.11.833.833

Published: 2006

Journal Articles

Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis

Keichiro Mihara, Moniruddin Chowdhury, Nanae Nakaju, Sachiko Hidani, Akihiro Ihara, Hideo Hyodo, Shin'ichiro Yasunaga, Yoshihiro Takihara, Akiro Kimura

Blood (2006) 107 (1): 305–308.

https://doi.org/10.1182/blood-2005-06-2393

Published: 2006

Journal Articles

Bmi-1 Expression Is Useful To Design Therapy and To Predict Prognosis in Patients with Acute Myeloid Leukemia.

Moniruddin Chowdhury, Keichiro Mihara, MD, Nanae Nakaju, Sachiko Fukumoto-Hidani, Yoshihiro Takihara, MD, Akiro Kimura, MD

Blood (2005) 106 (11): 3296.

https://doi.org/10.1182/blood.V106.11.3296.3296

Published: 2005

Journal Articles

L-Serine Produced by Mesenchymal Cells in the Bone Marrow Microenvironment Is a Trophic Factor for Hematopoietic Progenitor Cells.

Shotaro Iwamoto, MD, Keichiro Mihara, MD, Chihaya Imai, MD, Dario Campana, MD, PhD

Blood (2005) 106 (11): 590.

https://doi.org/10.1182/blood.V106.11.590.590

Published: 2005

Journal Articles

Development of Effective Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma with CD19-Specific Cytotoxic T Cells.

Keichiro Mihara, Kazuyoshi Yanagihara, Chihaya Imai, Akiro Kimura, Dario Campana

Blood (2004) 104 (11): 3277.

https://doi.org/10.1182/blood.V104.11.3277.3277

Published: 2004

Journal Articles

Bmi-1 Expression Predicts the Progression of Malignant Hematopoietic Stem Cells in Myelodysplastic Syndrome.

Keichiro Mihara, Nanae Nakaju, Sachiko Hidani, Moniruddin Chowdhury, Akihiro Ihara, Akiro Kimura

Blood (2004) 104 (11): 3425.

https://doi.org/10.1182/blood.V104.11.3425.3425

Published: 2004

Journal Articles

Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia

Jiann-Shiuh Chen, Elaine Coustan-Smith, Toshio Suzuki, Geoffrey A. Neale, Keichiro Mihara, Ching-Hon Pui, Dario Campana

Blood (2001) 97 (7): 2115–2120.

https://doi.org/10.1182/blood.V97.7.2115

Published: 2001

NARROW

Anti-CD38-CAR IPS-Derived Cytotoxic T Lymphocytes Efficiently Eliminate Myeloma Cells Treated with Daratumumab and Isatuximab in Vitro and In Vivo

T Cells Bearing Anti-CD19- and/or Anti-CD38-Chimeric Antigen Receptors Effectively Abrogate Primary Double-Hit Lymphoma Cells

All-Trans Retinoic Acid and Interferon-Alpha Increase CD38 Expression on Adult T-Cell Leukemia Cells and Sensitize Them to T Cells Bearing Anti-CD38 Chimeric Antigen Receptors

Adult T-Cell Leukemia/Lymphoma Cells Were Eliminated By T Cells With Anti-CD38 Chimeric Antigen Receptor Through CD38 Expression Induced By All-Trans Retinoic Acid

All-Trans Retinoic Acid Enhances the Cytotoxic Effect of T Cells with Anti-CD38 Chimeric Receptor in Acute Myeloid Leukemia

T-Cell Immunotherapy with a Chimeric Receptor Against CD38 Is Effective in Eliminating Myeloma Cells

B-Cell Lymphoma Cells Overexpressing BMI-1 Are Correlated with Drug Resistance through Enhanced Expression of Survivin and Are Effectively Eliminated by T Cells with Anti-CD38 Chimeric Receptor

Synergistic and Persistent Effect of T-Cell Immunotherapy with Anti-CD19 or Anti-CD38 Chimeric Receptor on B-Cell Lymphoma in Conjunction with Rituximab

Activated T Cell-Mediated Immunotherapy with a Chimeric Receptor Against CD38 in B-Cell Malignancies.

Interferon-γ Attenuates the Survival Activity of G-CSF through PI3K/Akt Signaling Pathway in Mouse Multipotent Progenitor Cells.

Mesenchymal Cells Determine the Response of Acute Lymphoblastic Leukemia Cells to L-Asparaginase.

Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis

Bmi-1 Expression Is Useful To Design Therapy and To Predict Prognosis in Patients with Acute Myeloid Leukemia.

L-Serine Produced by Mesenchymal Cells in the Bone Marrow Microenvironment Is a Trophic Factor for Hematopoietic Progenitor Cells.

Development of Effective Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma with CD19-Specific Cytotoxic T Cells.

Bmi-1 Expression Predicts the Progression of Malignant Hematopoietic Stem Cells in Myelodysplastic Syndrome.

Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only